This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy

Cell and Gene Therapy Report 2020: Viral and Non-viral Vectors

Posted by on 27 July 2020
Share this article

Viral and non-viral vectors are crucial gene delivery vehicles for cell and gene therapies, yet they are difficult to manufacture to a scale that meets the growing demand. Across vector characterization, raw materials and supply chain, there are many limitations and obstacles to consider.

In April 2020, we conducted a survey of cell and gene therapy professionals all over the world, to find out what difficulties they were experiencing, and which areas were in the greatest need of innovation.

The final report provides insight into the biggest opportunities and challenges surrounding viral and non-viral vector manufacturing which are ready to be addressed.

Key Insights

  • 59% of the participants are working with viral methods when considering viral gene therapy delivery.
  • 61% of the respondents see encountering stability issues as the main hurdle when cryopreserving their vectors.
  • Viral vectors used in production and plasmids were voted to be the most limiting when considering raw and starting materials used in viral vector manufacturing.

Click the image below to begin exploring the ebook.
Viral and Non-Viral Vectors Survey Report 2020

Share this article